Target molecules for future hidradenitis suppurativa treatment

Giamarellos-Bourboulis, EJ; Bettoli, V; Jemec, GBE; del Marmol, V; Marzano, AV; Prens, EP; Tzellos, T; Zouboulis, CC

Zouboulis, CC (corresponding author), Brandenburg Med Sch Theodor Fontane, Dept Dermatol, Dessau Med Ctr, Auenweg 38, D-06847 Dessau, Germany.; Zouboulis, CC (corresponding author), Brandenburg Med Sch Theodor Fontane, Dept Venereol, Dessau Med Ctr, Auenweg 38, D-06847 Dessau, Germany.; Zouboulis, CC (corresponding author), Brandenburg Med Sch Theodor Fontane, Dept Allergol, Dessau Med Ctr, Auenweg 38, D-06847 Dessau, Germany.; Zouboulis, CC (corresponding author), Brandenburg Med Sch Theodor Fo

EXPERIMENTAL DERMATOLOGY, 2021; 30 (): 18

Abstract

The registration of the tumour necrosis factor-alpha inhibitor adalimumab in 2015 was a major step forward in the treatment of hidradenitis suppurativ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索